Lessons from a randomised clinical trial for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 12, 2012, Pages 1582-1587

  Padayatchi, N ^a   Mac Kenzie, W R ^b   Hirsch Moverman, Y ^c   Feng, P J ^b   Villarino, E ^b   Saukkonen, J ^d   Heilig, C M ^a   Weiner, M ^e   El Sadr, W M ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Columbia University ^*  (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Clinical trial; HIV; Linezolid; Multidrug resistance; Treatment allocation; Tuberculosis

Indexed keywords

LINEZOLID; PLACEBO;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ACETAMIDES; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; PATIENT DROPOUTS; PILOT PROJECTS; RESEARCH DESIGN; SOUTH AFRICA; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84870317846     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0315     Document Type: Article

References (12)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008. http://wwwwhoint/tb/publications/2008/drs-report4-26feb08.pdf Accessed August 2012.
2. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/ 9789241501583-eng.pdf Accessed September 2012.
4. Diacon A H, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
5. Park I N, Hong S B, Oh Y M, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-704.
6. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J Infect 2006; 52: 92-96.
7. Schecter G F, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
8. Heilig C M, Chia D, El-Sadr W M, et al. Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis. IRB 2011; 33: 10-17.
9. Mitnick C D, Castro K G, Harrington M, Sacks L V, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007; 4: e292.
10. Zhang Y, Yew W W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-1330.
11. Cramm J M, Finkenflugel H J, Moller V, Nieboer A P. TB treatment initiation and adherence in a South African community influenced more by perceptions than by knowledge of tuberculosis. BMC Public Health 2010; 10: 72.
12. Hasker E, Khodjikhanov M, Sayfiddinova S, et al. Why do tuberculosis patients default in Tashkent City, Uzbekistan? A qualitative study. Int J Tuberc Lung Dis 2010; 14: 1132-1139.